Arcutis Biotherapeutics, Inc.
ARQT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001787306
In the last 90 days, Arcutis Biotherapeutics, Inc. insiders filed 0 open-market purchases and 12 sales; 272 institutions reported holding it in 13F filings for Q2 2026, worth $3.45B in total; no superinvestor holds it.
13F holders, Q3 2022
Institutional positions in Arcutis Biotherapeutics, Inc. as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 139
- +24 vs. Q2 2022
- Shares held
- 59.4M
- +10.3M (+20.9%) vs. Q2 2022
- Total value
- $1.13B
- +$88.4M (+8.5%) vs. Q2 2022
- New holders
- 35
- 68 more added
- Sold out
- 11
- 19 more reduced
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ARQT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 272 | $3.45B |
| Q1 2026 | 270 | $3.12B |
| Q4 2025 | 283 | $3.75B |
| Q3 2025 | 239 | $2.37B |
| Q2 2025 | 230 | $1.78B |
| Q1 2025 | 241 | $1.97B |
| Q4 2024 | 208 | $1.79B |
| Q3 2024 | 188 | $1.20B |
| Q2 2024 | 186 | $1.18B |
| Q1 2024 | 168 | $1.24B |
| Q4 2023 | 133 | $327.1M |
| Q3 2023 | 134 | $356.7M |
| Q2 2023 | 136 | $684.0M |
| Q1 2023 | 144 | $787.6M |
| Q4 2022 | 141 | $979.6M |
| Q3 2022 | 139 | $1.13B |
| Q2 2022 | 115 | $1.05B |
| Q1 2022 | 106 | $929.8M |
| Q4 2021 | 93 | $961.8M |
| Q3 2021 | 103 | $1.09B |
| Q2 2021 | 102 | $1.24B |
| Q1 2021 | 94 | $1.35B |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding Arcutis Biotherapeutics, Inc.; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Rafferty Asset Management, LLC | 173,983 | $3.33M | 0.04% | +131,606+310.6% | Added |
| 1492 Capital Management LLC | 178,320 | $3.41M | 2.46% | +361+0.2% | Added |
| Price T Rowe Associates Inc | 179,294 | $3.43M | 0.00% | −273,763−60.4% | Reduced |
| Goldman Sachs Group Inc | 183,297 | $3.50M | 0.00% | +87,119+90.6% | Added |
| Sectoral Asset Management Inc | 220,985 | $4.22M | 0.83% | +40,969+22.8% | Added |
| Jacobs Levy Equity Management, Inc | 232,213 | $4.44M | 0.04% | +232,213 | New |
| MPM Oncology Impact Management LP | 257,185 | $4.92M | 1.16% | −1,315−0.5% | Reduced |
| Sofinnova Investments, Inc. | 274,330 | $5.24M | 0.33% | +274,330 | New |
| Charles Schwab Investment Management Inc | 291,093 | $5.56M | 0.00% | +73,833+34.0% | Added |
| Dimensional Fund Advisors LP | 313,943 | $6.00M | 0.00% | +1,335+0.4% | Added |
| AXA S.A. | 337,595 | $6.45M | 0.03% | +113,963+51.0% | Added |
| Northern Trust Corp | 373,701 | $7.14M | 0.00% | +58,643+18.6% | Added |
| EcoR1 Capital, LLC | 415,322 | $7.94M | 0.23% | −480,181−53.6% | Reduced |
| Westfield Capital Management Co LP | 469,774 | $8.98M | 0.07% | +469,774 | New |
| Rubric Capital Management LP | 472,047 | $9.02M | 0.45% | +245,701+108.6% | Added |
| Ensign Peak Advisors, Inc | 489,345 | $9.35M | 0.02% | +109,450+28.8% | Added |
| Nuveen Asset Management, LLC | 532,875 | $10.2M | 0.00% | +171,732+47.6% | Added |
| Woodline Partners LP | 550,396 | $10.5M | 0.15% | +550,396 | New |
| Pivotal bioVenture Partners Investment Advisor LLC | 569,041 | $10.9M | 3.97% | 00.0% | Unchanged |
| American Century Companies Inc | 582,936 | $11.1M | 0.01% | +18,292+3.2% | Added |
| Ameriprise Financial Inc | 654,678 | $12.5M | 0.00% | +110,490+20.3% | Added |
| Allspring Global Investments Holdings, LLC | 728,364 | $13.9M | 0.02% | +98,610+15.7% | Added |
| Geode Capital Management, LLC | 734,244 | $14.0M | 0.00% | +165,578+29.1% | Added |
| Avidity Partners Management LP | 794,500 | $15.2M | 0.33% | +794,500 | New |
| Franklin Resources Inc | 798,996 | $15.3M | 0.01% | +5,100+0.6% | Added |
| GW&K Investment Management, LLC | 908,913 | $17.4M | 0.19% | +232,235+34.3% | Added |
| Cormorant Asset Management, LP | 1,000,000 | $19.1M | 1.34% | +1,000,000 | New |
| Polar Capital Holdings Plc | 1,309,268 | $25.0M | 0.20% | −96,528−6.9% | Reduced |
| Jennison Associates LLC | 1,389,616 | $26.6M | 0.03% | +954,597+219.4% | Added |
| Logos Global Management LP | 1,525,000 | $29.1M | 3.59% | +525,000+52.5% | Added |
| Pictet Asset Management SA | 1,602,786 | $30.6M | 0.05% | +679,892+73.7% | Added |
| Vanguard Group Inc | 2,252,939 | $43.1M | 0.00% | +454,276+25.3% | Added |
| State Street Corp | 2,655,235 | $50.7M | 0.00% | +1,258,810+90.1% | Added |
| OrbiMed Advisors LLC | 2,800,000 | $53.5M | 1.06% | −1,981,646−41.4% | Reduced |
| Bain Capital Life Sciences Investors, LLC | 3,000,000 | $57.3M | 6.84% | 00.0% | Unchanged |
| Point72 Asset Management, L.P. | 3,785,277 | $72.3M | 0.31% | +1,797,846+90.5% | Added |
| BlackRock Inc. | 5,081,744 | $97.1M | 0.00% | +503,591+11.0% | Added |
| Frazier Life Sciences Management, L.P. | 8,684,232 | $166.0M | 12.78% | +250,000+3.0% | Added |
| FMR LLC | 8,929,231 | $170.6M | 0.02% | +1,216,551+15.8% | Added |
| Omega Fund Management, LLC | 0 | $0 | 0.00% | −623,836−100.0% | Sold out |
| Pura Vida Investments, LLC | 0 | $0 | 0.00% | −100,000−100.0% | Sold out |
| UBS Oconnor LLC | 0 | $0 | 0.00% | −66,635−100.0% | Sold out |
| HighVista Strategies LLC | 0 | $0 | 0.00% | −34,462−100.0% | Sold out |
| SG3 Management, LLC | 0 | $0 | 0.00% | −22,500−100.0% | Sold out |
| Caption Management, LLC | 0 | $0 | 0.00% | −5,910−100.0% | Sold out |
| Point72 Hong Kong Ltd | 0 | $0 | 0.00% | −1,197−100.0% | Sold out |
| Cutler Group LP | 0 | $0 | 0.00% | −800−100.0% | Sold out |
| Geneos Wealth Management Inc. | 0 | $0 | 0.00% | −460−100.0% | Sold out |
| Captrust Financial Advisors | 0 | $0 | 0.00% | −95−100.0% | Sold out |
| Parallel Advisors, LLC | 0 | $0 | 0.00% | −7−100.0% | Sold out |